




EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# First anniversary of PRIME: experience so far

Friday 19 May 2017

European Medicines Agency, London, United Kingdom



# Agenda

---

Chairs: Tomas Salmonson (CHMP chair) and Jordi Llinares Garcia (EMA)

<b>09:00 – 09:15</b>	<b>Welcome and introduction</b>	Guido Rasi (EMA) Zaide Frias (EMA)
<b>09:15 – 10:15</b>	<b>Eligibility to PRIME</b>	
	Overview of one-year experience of PRIME eligibility assessments – 20'	Robert Hemmings (SAWP chair)
	Industry experience and feedback on the eligibility procedure – 15'	Aimad Torqui (EFPIA)
	Q&A – 25'	
<b>10:15 – 11:30</b>	<b>Kick-off meetings and support to PRIME medicines</b>	
	How have eligible products benefited from PRIME so far? - 15'	Jordi Llinares Garcia (EMA)
	Industry perspective – 40'	Rizwana Sproule (Kite Pharma) James Kennard (Biogen) Simon Bennett (EFPIA)
	Q&A – 20'	
	<i>Speakers will be joined by the chairs of the Agency's scientific committees</i>	
<b>11:30 – 12:00</b>	<b>Coffee break</b>	
<b>12:00 – 13:45</b>	<b>Panel discussion</b>	Moderator: Tomas Salmonson (CHMP chair)
	This panel discussion will assemble stakeholders to provide reflexions on the scheme.	
	Panellists: Emma Du Four (EFPIA) Robert Hemmings (SAWP chair) Jordi Llinares Garcia (EMA) François Meyer (HAS) Martina Schübler-Lenz (CAT chair) Ad Schuurman (MEDEV) Christos Sotirelis (EURORDIS) Spiros Vamvakas (EMA)	
<b>13:45 – 14:00</b>	<b>Closing remarks</b>	Tomas Salmonson (CHMP chair) Jordi Llinares Garcia (EMA)

# List of speakers and panellists

---

<b>Simon Bennett</b>	Biogen, EFPIA
<b>Emma Du Four</b>	Abbvie, EFPIA
<b>Zaide Frias</b>	Head of Human Medicines Evaluation, EMA
<b>Robert Hemmings</b>	SAWP chair
<b>James Kennard</b>	Biogen
<b>Jordi Llinares Garcia</b>	Head of Scientific and Regulatory Management, EMA
<b>Dirk Mentzer</b>	PDCO chair
<b>François Meyer</b>	Haute Autorité de Santé, France
<b>June Raine</b>	PRAC chair
<b>Guido Rasi</b>	Executive director, EMA
<b>Tomas Salmonson</b>	CHMP chair
<b>Martina Schüßler-Lenz</b>	CAT chair
<b>Ad Schuurman</b>	Chair, Medicines Evaluation Committee (MEDEV)
<b>Bruno Sepodes</b>	COMP chair
<b>Christos Sotirelis</b>	European Organisation for Rare Diseases (EURORDIS)
<b>Rizwana Sproule</b>	Kite Pharma
<b>Aimad Torqui</b>	MSD, EFPIA
<b>Spiros Vamvakas</b>	Head of Scientific Advice, EMA

# Practical information

## Venue

The European Medicines Agency can be reached:

- **By Underground**

The nearest stop for Churchill Place is Canary Wharf station on the Jubilee Line. From East exit (NB. This is the closest exit to 30 Churchill Place): exit the station and turn left into Upper Bank Street, turn right at Canada Square and continue straight into Churchill Place.

- **By Docklands Light Railway (DLR)**


The Agency is a short walk from Canary Wharf station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton. Exit into The South Colonnade, turn left towards Canada Square continuing straight into Churchill Place.

- **By car**

There are no parking facilities at 30 Churchill Place and it is recommended that you take public transport. However, four nearby public car parks are operated by Canary Wharf. Rates and further information can be found on the Canary Wharf website:

<http://canarywharf.com/getting-here/parking/>

## Map



## Arrival at the Agency

---

On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to access our industry lounge, which you are welcome to utilise during your visit. The industry lounge is located through the sliding doors to the right of the reception desk past the security turnstiles. Your EMA contact point will meet you here.

## Physical disability

---

Let us know if you would like any specific help or information that would make your stay more comfortable. We will be very happy to help.

## Registration

---

We strongly advise you to arrive up to 30 minutes before the start of the meeting, to allow you time for registration and settling down.

## Meeting room

---

You will be able to sit wherever you wish; note that the only reserved seats are for the speakers, panellists and organisers of the meeting.

## Presentations

---

We will not circulate printouts of speakers' presentations. However, you will be able to download them from the Agency's website approximately two weeks after the end of the meeting.

## Wi-Fi access & Laptop computers

---

Wi-Fi is available throughout the EMA. Login details can be found on the back of your EMA access pass.

## Media disclaimer

---

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on European Union. The Agency herewith informs attendees that this particular meeting will be recorded and broadcast. For more information about processing of personal data by EMA, please visit the website:

[http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general\\_content\\_000516.jsp&mid](http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general_content_000516.jsp&mid)  
or contact  
[dataprotection@ema.europa.eu](mailto:dataprotection@ema.europa.eu)

By attending this meeting you consent to any recording or broadcast.

## Conference venue and secretariat

---

European Medicines Agency  
30 Churchill Place, Canary Wharf  
London E14 5EU, United Kingdom  
**Telephone** +44 (0)20 3660 8429 | **Facsimile** +44 (0)20 3660 5510  
**E-mail** [PRIME2017mtg@ema.europa.eu](mailto:PRIME2017mtg@ema.europa.eu) | **Website** [www.ema.europa.eu](http://www.ema.europa.eu)

## European Medicines Agency

30 Churchill Place  
Canary Wharf  
London E14 5EU  
United Kingdom

**Telephone** +44 (0)20 3660 6000

**Facsimile** +44 (0)20 3660 5555

**Send a question** [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact)

**[www.ema.europa.eu](http://www.ema.europa.eu)**

First anniversary of PRIME: experience so far  
EMA/177510/2017  
Human Medicines Evaluation

© European Medicines Agency, 2017.  
Reproduction is authorised provided the source is acknowledged.

